Target 27c, page-3

Prima Biomed Ltd. (PBMD) Research Coverage Started at Roth Capital

December 30th, 2015 - By Maddie Sorensen - 0 comments
Roth Capital started coverage on shares of Prima Biomed Ltd. (NASDAQBMD) in a research note issued to investors on Wednesday,StockTargetPrices.com reports. The firm set a “buy” rating and a $6.00 price target on the stock. Roth Capital’s price target would indicate a potential upside of 440.54% from the company’s current price.
Shares of Prima Biomed (NASDAQBMD) traded up 1.83% during mid-day trading on Wednesday, reaching $1.11. The company had a trading volume of 542,218 shares. The stock has a 50 day moving average of $1.14 and a 200-day moving average of $1.25. Prima Biomed has a one year low of $0.42 and a one year high of $6.48. The firm’s market capitalization is $73.05 million.
Several other research analysts also recently commented on PBMD. HC Wainwright started coverage on shares of Prima Biomed in a research report on Wednesday, October 14th. They set a “buy” rating and a $3.00 price objective for the company. FBR & Co. started coverage on shares of Prima Biomed in a research report on Thursday, December 3rd. They set an “outperform” rating and a $6.00 price objective for the company.